



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/724,223	12/01/2003	Jon Elliot Adler	54072D2	9750

21967 7590 10/11/2006

HUNTON & WILLIAMS LLP
INTELLECTUAL PROPERTY DEPARTMENT
1900 K STREET, N.W.
SUITE 1200
WASHINGTON, DC 20006-1109

EXAMINER

BRANNOCK, MICHAEL T

ART UNIT PAPER NUMBER

1649

DATE MAILED: 10/11/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/724,223

Applicant(s)

ADLER ET AL.

Examiner

Michael Brannock

Art Unit

1649

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 04 May 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 235-286 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 235-286 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 01 December 2003 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date <u>050404</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Status of Application: Claims and Amendments

Applicant is notified that the amendments put forth on 12/1/2003, have been entered in full.

Claims 235-286 are pending and under examination in this Office Action.

Specification

The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code, see page 16 for example. Applicant is required to delete the embedded hyperlinks and/or other form of browser-executable code. See MPEP 608.01.

Claim Objections

Claim 235 is objected to because of the following informalities: the phrase "based its" in claim 235(2) appears to be missing the word "on", i.e. "based on its".

Appropriate correction is required.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 235-286 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 286, and dependent claims require a compound that "putatively" modulates or elicits human T1R1-associated taste. It is unclear what limitations Applicant intends the world putatively to add to the claims, and nor is such explained in the specification. Thus, an artisan

Art Unit: 1649

could not be sure whether he or she was practicing or infringing on Applicant's claims.

Similarly, the phrase "T1R1-associated taste" renders the claims indefinite as there is no particular description provided in the specification which distinctly defines the phrase.

Claims 235 and 244 require that the nucleic acid hybridize under stringent conditions. The term stringent conditions is a relative term and encompasses conditions of varying degrees of stringency - such conditions determining the bounds of the claim. However, the art does not provide an unambiguous definition of the term "stringent conditions" and neither is such a definition given for the term in the specification which puts forth the metes and bounds of the claim Applicant is seeking protection for. The term appears to be defined only by way of example at page 30. It is suggested that the claim recite the actual conditions that applicant considers to be stringent, e.g., salt concentration and temperature conditions of incubations and washes.

In claim 270, the phrase "ion polarization" lacks sufficient antecedent basis, however this appears to be a typographical error, in that the claim may have been intended to depend from claim 269 and not claim 268.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 235-286 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described

Art Unit: 1649

in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The claims are directed to methods for identifying a compound that putatively modulates or elicits human T1R1-associated taste in a human subject, yet the specification has not taught what particularly human T1R1-associated taste is. The instant claims are directed to a polypeptide of SEQ ID NO: 17 which is termed hT1R1. The specification asserts it is believed that T1R protein family members are components of the taste transduction pathway and may be involved in taste detection of sweet substances and/or other taste modalities but the specification does not teach what or how to measure "human T1R1-associated taste" as this phrase relates to the polypeptide of SEQ ID NO: 17. Additionally, claim 235 requires that the identified compound modulate the activation of the polypeptide by another compound, yet no such compounds have been taught in the specification. The specification has not taught where to obtain such and it does not assert that any particular compound would have this property, yet an artisan would need such a compound to practice the invention. Furthermore, the claims require fragments of the polypeptide of SEQ ID NO: 17 or other polypeptides that are encoded by polynucleotides comprising as few as 500 polynucleotides of a polynucleotide SEQ ID NO: 15 or 16, the specification has not provided sufficient information so as to be able to know which of such polypeptides could be used in the claimed assays. Claim 244 requires only that the polypeptide be encoded by a polynucleotide that need only hybridize to a polynucleotide comprising as few as 500 polynucleotides of a polynucleotide SEQ ID NO: 15 or 16. The instant specification appears to simply suggest to the artisan that art-recognized procedures for screening GPCRs (e.g. pages 26 and 49-62) are sufficient to identify functional variants of SEQ ID NO: 4.

Art Unit: 1649

However, Hoon *et al.*, *Cell* 96(541-551)1999, report that “We have attempted to determine the ligand/tastant specificity of TR1 and TR2 using a variety of strategies but have been hampered by the difficulty of functionally expressing these molecules in heterologous system see col 1 of page 547”. The art regarding T1R receptors, as exemplified by Hoon *et al.*, recognizes the complexity, unpredictability, and non-routine nature of the work involved in trying to assay functional T1R receptors. The instant specification has provided only general guidance to the skilled artisan -such guidance does not supply the artisan with the detailed methods one would need to possess in order to screen for functional variants. Further, the specification has offered no working example of such a screening method. While, it may be reasonable that the instant specification is enabling for variants that are at least 90% identical to SEQ ID NO: 17, see copending Application 09799629, the scope of the instant claims is vastly wider than such and does not appear to be supported by and adequate disclosure.

Due to the large quantity of experimentation necessary to generate the infinite number of variants recited in the claims and screen same for activity, the lack of direction/guidance presented in the specification regarding what particular activity is intended to be human T1R1-associated taste activity, the absence of working examples directed to same, the complex nature of the invention, the state of the prior art which establishes the unpredictability of the and the difficulties encountered in screening T1Rs, exemplified by Hoon *et al.* and the breadth of the claims which fail to recite any structural or functional limitations, undue experimentation would be required of the skilled artisan to make and/or use the claimed invention.

Art Unit: 1649

Claims 235-286 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. As set forth above, the claims require requires that the identified compound modulate the activation of the polypeptide by another compound, yet no such specific binding compounds have been taught in the specification. The specification has not taught where to obtain such and it does not assert that any particular compound would have this property. Thus the one skilled in art would not recognize that Applicant was in possession of such compounds that are needed to practice the claimed methods.

Art Unit: 1649

Additional references of interest: U.S. Patent No: 7022488, SEQ ID NO: 197

Conclusion


The Art Unit location of your application in the USPTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Art Unit 1649.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Brannock, Ph.D., whose telephone number is (571) 272-0869. The examiner can normally be reached on Mondays through Fridays from 10:00 a.m. to 4:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres, Ph.D., can be reached at (571) 272-0867. Official papers filed by fax should be directed to **571-273-8300**.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

MB


September 28, 2006


JANET L. ANDRES
SUPERVISORY PATENT EXAMINER